Total Funding
66
7
Total FundingSeries C raised
Growth Score
-4 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
795691
Pronota develops diagnostic devices for the early detection of conditions such as heart failure, pre-eclampsia and sepsis.
About the Company
Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis.
Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of
investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare.
Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.
